Associated Genetic Biomarkers
Associated Diseases
Associated Pathways

Overview

Location [1]
8p11.23
Pathways
Kinase fusions, Receptor tyrosine kinase/growth factor signaling
Protein [2]
Fibroblast growth factor receptor 1
Synonyms [1]
OGD, BFGFR, CEK, HBGFR, CD331, HRTFDS, FLT2, KAL2, FLG, N-SAM, HH2, FGFBR, FLT-2, ECCL, FGFR-1, bFGF-R-1

FGFR1 (fibroblast growth factor receptor type 1) encodes the fibroblast growth factor receptor type 1 protein, a receptor tyrosine kinase. FGFR1 and other FGFR TKs play crucial roles in development and have been shown in cancers to be deregulated by amplification, point mutation, or translocation (PMID: 20094046).  Amplification or activation of FGFR1 has been reported in many cancers, including oral squamous cell carcinoma (PMID: 16807070), breast cancer (PMID: 20179196), esophageal squamous cell carcinoma (PMID: 12147242), ovarian cancer (PMID: 17699850), bladder cancer (PMID: 11389083), prostate cancer (PMID: 14614009), and lung cancer, predominantly in the squamous subtype (PMID: 21666749; PMID: 17982442; PMID: 21160078).

FGFR1 is altered in 3.63% of all cancers with breast invasive ductal carcinoma, lung adenocarcinoma, invasive breast carcinoma, colon adenocarcinoma, and squamous cell lung carcinoma having the greatest prevalence of alterations [3].

FGFR1 GENIE Cases - Top Diseases

The most common alterations in FGFR1 are FGFR1 Amplification (2.34%), FGFR1 Mutation (1.20%), FGFR1 Loss (0.33%), FGFR1 Exon 12 Mutation (0.20%), and FGFR1 Fusion (0.18%) [3].

FGFR1 GENIE Cases - Top Alterations

Significance of FGFR1 in Diseases

Malignant Solid Tumor +

Urothelial Carcinoma +

Breast Carcinoma +

Non-Small Cell Lung Carcinoma +

Acute Lymphoblastic Leukemia +

Cholangiocarcinoma +

Squamous Cell Lung Carcinoma +

Gastric Carcinoma +

Adenocarcinoma Of The Gastroesophageal Junction +

B-Cell Acute Lymphoblastic Leukemia +

Cancer +

Bladder Carcinoma +

Acute Myeloid Leukemia +

Endometrial Carcinoma +

Transitional Cell Carcinoma +

Multiple Myeloma +

Gastric Adenocarcinoma +

Esophageal Carcinoma +

Colorectal Carcinoma +

Head And Neck Squamous Cell Carcinoma +

Pancreatic Carcinoma +

Sarcoma +

Non-Hodgkin Lymphoma +

Gastrointestinal Stromal Tumor +

Myelodysplastic Syndromes +

Myeloid Neoplasm +

Mixed Phenotype Acute Leukemia +

Dysembryoplastic Neuroepithelial Tumor +

Pilomyxoid Astrocytoma +

Neuronal And Mixed Neuronal-Glial Tumors +

Invasive Breast Carcinoma +

Pilocytic Astrocytoma +

Anaplastic Oligodendroglioma +

Small Cell Lung Carcinoma +

Esophageal Squamous Cell Carcinoma +

Ganglioglioma +

Low Grade Glioma +

Nasal Cavity And Paranasal Sinus Carcinoma +

Urethral Urothelial Carcinoma +

Laryngeal Squamous Cell Carcinoma +

Malignant Laryngeal Neoplasm +

Glioma +

Malignant Glioma +

Ovarian Carcinoma +

Astrocytic Tumor +

Glioblastoma +

Diffuse Glioma +

Cervical Carcinoma +

Melanoma +

Malignant Uterine Neoplasm +

Lung Carcinoma +

Bladder Urothelial Carcinoma +

Infiltrating Renal Pelvis And Ureter Urothelial Carcinoma +

Malignant Salivary Gland Neoplasm +

Head And Neck Carcinoma +

Anaplastic Astrocytoma +

Pancreatic Adenocarcinoma +

Soft Tissue Sarcoma +

Lip And Oral Cavity Carcinoma +

Oral Cavity Carcinoma +

Oral Cavity Squamous Cell Carcinoma +

Gallbladder Carcinoma +

Oropharyngeal Carcinoma +

Oropharyngeal Squamous Cell Carcinoma +

Extrahepatic Cholangiocarcinoma +

Hepatobiliary Neoplasm +

Malignant Hepatobiliary Neoplasm +

B-Cell Non-Hodgkin Lymphoma +

Lymphocytic Neoplasm +

Bile Duct Carcinoma +

Intrahepatic Cholangiocarcinoma +

Hematopoietic And Lymphoid Malignancy +

Myeloproliferative Neoplasm +

B-Cell Lymphoblastic Lymphoma +

Bronchogenic Carcinoma +

Chronic Myeloid Leukemia +

Chronic Myelomonocytic Leukemia +

Gangliocytoma +

Histiocytic And Dendritic Cell Neoplasm +

Hypopharyngeal Squamous Cell Carcinoma +

Low-Grade Neuroepithelial Tumor, NOS +

Lymphoblastic Lymphoma +

Mixed Phenotype Acute Leukemia, B/Myeloid, NOS +

Mixed Phenotype Acute Leukemia, T/Myeloid, NOS +

Myelodysplastic Syndrome With Excess Blasts-2 +

Nasopharyngeal Carcinoma +

Non-Muscle Invasive Bladder Carcinoma +

Renal Pelvis Urothelial Carcinoma +

Secondary Acute Myeloid Leukemia +

T-Cell Acute Lymphoblastic Leukemia +

T-Cell Lymphoblastic Lymphoma +

Therapy-Related Acute Myeloid Leukemia +

Ureter Urothelial Carcinoma +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.